Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
May 07 2024 - 7:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
07
May 2024 - “EMTN programme: publication of base
prospectus”
|
99.1
EMTN programme: publication of base prospectus
7 May 2024: Haleon plc
(the "Company") (LSE/NYSE: HLN) today announces that, following a
routine annual update, the base prospectus dated 3 May 2024
regarding Haleon UK Capital plc's and Haleon Netherlands Capital
B.V.'s £10,000,000,000 Euro Medium Term Note ("EMTN")
Programme, guaranteed by the Company, has been published (the "Base
Prospectus").
A copy of the Base Prospectus is available for inspection at and
can be downloaded from:
https://www.haleon.com/investors/debt-investors.
Enquiries:
|
Investors
|
Media
|
|
Sonya Ghobrial
|
+44 7392 784784
|
Zoe Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Gemma Thomas
|
+44 7985175048
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
Disclaimer
Please note that the information contained in the Base Prospectus
may be addressed to and/or targeted at persons who are residents of
particular countries (specified in the Base Prospectus) only and is
not intended for use and should not be relied upon by any person
outside these countries and/or to whom the offer contained in the
Base Prospectus is not addressed. Prior to relying on the
information contained in the Base Prospectus, you must ascertain
from the Base Prospectus whether or not you are part of the
intended addressees of the information contained in the Base
Prospectus.
Your right to access this service is conditional upon complying
with the above requirement.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
May 07, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Apr 2024 to May 2024
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From May 2023 to May 2024
